The North America Pruritus Therapeutics Market would witness market growth of 3.7% CAGR during the forecast period (2023-2030).
Therapeutics used to treat pruritus are referred to as pruritus therapeutics. The itching of the skin caused by various ailments, including dry skin, allergies, and other ailments, is known as pruritus. When pruritus endures longer, it usually indicates a more serious underlying cause. Eczema, or atopic dermatitis (AD), can be brought on by an increased inflammatory reaction to various potential irritants, including dust, environmental contaminants, animals, and specific foods. Typical contact dermatitis-inducing products include watches, soaps, clothes, and jewelry, potentially irritating substances.
The pruritus results from stimulation from dermal tissue-free nerve endings that are transferred through the spinal cords, C-fibers, and the spinothalamic tract. Itching or pruritus is the result of this process. Since this condition is a sign of neurologic disorders, chronic renal failure, cholestasis, systemic infections, cancers, endocrine diseases, exposure to certain medicines, and hepatitis, it is also a symptom of those disorders. A thorough evaluation combining a clinical examination and laboratory tests is necessary to determine the actual cause of pruritus. These tests may be dermatologic, systemic, neurogenic, or psychological. The market includes selling dermatological products intended to treat pruritus. Corticosteroids have been used externally by medical experts to treat pruritus. The first line of treatment for skin conditions such as pruritus, allergic contact dermatitis, and AD has been corticosteroids.
In a study by the National Library of Medicine on the prevalence of atopic dermatitis in Canada, 76 patients with AD in the state of Ontario participated in a survey to learn more about the disease's severity, visits to the doctor, use of over-the-counter medications, household costs, and absenteeism related to the condition. Furthermore, 38.0% of the adult population in the U.S., or 96 million people, had prediabetes. The high prevalence of diabetes in the region, which may also increase the risk of pruritus, is expected to provide potential opportunities for the market.
The US market dominated the North America Pruritus Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3.0 billion by 2030. The Canada market is poised to grow at a CAGR of 6% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 5.1% during (2023 - 2030).
Based on Disease Type, the market is segmented into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria and Others. Based on Product, the market is segmented into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Pruritus Therapeutics Market is Projected to reach USD 11.2 Billion by 2030, at a CAGR of 4.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Novartis AG, Pfizer, Inc., Sanofi S.A., Astellas Pharma, Inc., Cara Therapeutics, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceuticals Industries Ltd., Amgen, Inc., and AbbVie, Inc.
By Disease Type
By Product
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
